logo
Clinical and biological insights in HIV-associated cardiovascular disease in the era of highly active antiretroviral therapy
HIV therapy in 2003
Pathogenesis of HIV-associated heart disease
Immunopathogenesis of HIV-related heart muscle disease
Mediators in HIV-associated cardiovascular disease
Use of the transgenic mouse in models of AIDS cardiomyopathy
Incidence of the involvement of the cardiovascular system in HIV infection
HIV and direct damage of organs
Atherosclerosis and HIV in the highly active antiretroviral therapy era
Coronary heart disease in HIV-infected patients in the highly active antiretroviral treatment era
Kawasaki-like syndromes and other vasculitic syndromes in HIV-infected patients
Overview on the incidence and the characteristics of HIV-related opportunistic infections and neoplasms of the heart
Clinical and therapeutical follow-up of HIV-associated pulmonary hypertension
Cardiovascular risk factors, monitoring, and therapy for HIV-infected patients
Effect of exercise and strength training on cardiovascular status in HIV-infected patients receiving highly active antiretroviral therapy
Nutritional aspects of HIV-infected children receiving highly active antiretroviral therapy
HIV lipodystrophy
Clinical impact of HIV-related lipodystrophy and metabolic abnormalities on cardiovascular disease
Cytokine production in women with antiretroviral treatment-associated breast fat accumulation and limb wasting
Evaluation and management of metabolic and coagulative disorders in HIV-infected patients receiving highly active antiretroviral therapy
The Pavia consensus statement